Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
A meta-analysis of whole genome linkage screens in multiple sclerosis.
Restoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.
Brain reserve and cognitive reserve in multiple sclerosis: What you've got and how you use it.
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1.
Mitoxantrone-induced suicidal erythrocyte death.
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
[The first experience of the use the Russian Β-interferon-1b biosimilar (infibeta) in the daily practice of the Moscow Center of Multiple Sclerosis.]
Ofatumumab Dose-finding in RRMS Patients
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
Food and Drug Administration drug insert for Campath (alemtuzumab)
Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review.
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review.
Laquinimod Phase IIa Study in Active Crohn's Disease
FDA Accepts Filing of BETACONNECT™* for Relapsing-Remitting Multiple Sclerosis Patients Taking BETASERON® (interferon beta-1b)
Late relapse of non-seminomatous testicular cancer during treatment of multiple sclerosis with interferon β-1a: A case report.
Fingolimod is a potential novel therapy for multiple sclerosis.
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis.
UPDATE 1-Teva Pharmaceutical banks on thrice-weekly Copaxone
Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease.
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
Gustatory Dysfunction in Multiple Sclerosis
Colestipol May Quickly Eliminate Teriflunomide

Pages